CCR9/CCL25 can also activate Ras/Raf/MARK and RhoA/Rock signals to strengthen the degradation of ECM and change the cytoskeleton arrangement, thus enhancing tumor cell motility (Golec, Henao Caviedes & Baldwin, 2016). The gene discussed is MARK1; the disease is neoplasm.